Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.
about
Some vexations that challenge viral immunologyUpdate on Hepatitis B Virus Infection: Focus on TreatmentIntrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis BSymbiotic chemo- and immuno-therapy for hepatitis B and C virusesPrevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapyHepatitis B virus and its sexually transmitted infection - an update.Natural killer cell activation contributes to hepatitis B viral control in a mouse model.Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) is associated with immune phases of patients with chronic hepatitis B.Hurdles to the Development of Effective HBV Immunotherapies and HCV VaccinesContradictory immune response in post liver transplantation hepatitis B and C.Natural Killer Cells in Viral Hepatitis.Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients.Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance.Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production.HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2.Regulatory T Cells in Hepatitis B and C Virus Infections.HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.Interferon-stimulated gene 15 in hepatitis B-related liver diseases.SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B.Immunology in the liver--from homeostasis to disease.Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.Novel targets for hepatitis B virus therapy.Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin.Functional restoration of CD56(bright) NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B.HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C.Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B.Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy.Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis BInterferon-α inhibits cell migration and invasion and induces the expression of antiviral proteins in Huh-7 cells transfected with hepatitis B virus X gene-expressing lentivirus.Comprehensive investigation of cytokine- and immune-related gene variants in HBV-associated hepatocellular carcinoma patients.A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study.Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach.Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.
P2860
Q24672537-AB6307BC-272C-44F8-89C1-9C970F92C56EQ26781990-5AF8919C-BB18-4755-B80E-0429F1E64964Q27318089-F9A6C727-E716-4EDB-B0DE-45F47844287DQ27468956-332A2311-C230-403C-9851-98D55600F8A2Q28076466-08CCD80B-17FE-4E90-BC9B-12C6B6DE58D9Q30235028-1F4D4AE6-1B3E-4895-BE07-658965AEB036Q33670723-FACD2CBE-4B3C-4D9D-9AB8-F62ACCAFE21EQ33761546-BC9773F3-2BBE-475B-95DE-237EE021F059Q33840260-94BE1063-586F-4CE5-9F24-61DE4AAF48DFQ34152074-0554BA5B-D029-4A15-94FC-A093B3D550DFQ34505690-9D7F08A5-356C-43E8-934D-22E5B41E6BA7Q35810713-8FFD3F68-FAC0-4698-B668-A87A63E97F63Q35911913-273D5090-D4E2-42F4-A78B-B87FAC372FAEQ36101272-AF1E2D04-15FA-478D-86B9-31DAE43F4CF3Q36272899-09E1D905-DC69-4762-ABF2-A543C1387789Q36914497-B83826AA-14AD-453D-9C09-449322A4B692Q37437190-BB7DD66A-DB3C-4053-8D91-B0379F34F68EQ37541438-6716F13A-FEB2-4C35-9C4B-23CED19679B2Q37708188-30D484B7-1DF2-4803-AF19-A3BFAE346623Q37708705-26DD8630-7E86-4358-B57D-2106A817D07FQ37725585-806018AF-E6C9-4E20-B2B7-06D66D68D970Q38693925-930F0E4E-81AE-49E7-9843-B33AB7C6D2AEQ38805093-B9D8A462-E818-43DF-AAB0-1750563BECE8Q39067316-1BA9FEE9-2EB1-4D2D-98E0-3D4F7C5B4C6BQ39136809-621A62AA-6DAE-473F-BF35-9F5877A8CFC1Q40068271-14ACC00E-DB17-4A1B-ACB7-457360C4829FQ40150197-7D72858C-5A36-4B2F-A4E0-40C995094692Q40152820-A81DA67D-CEC7-44AA-8E15-B1FF4C32E8DEQ40476048-05C08ABC-421F-497A-96A8-82C679CE2C97Q40523304-B624842A-459E-4371-87DD-DB40ABCF25EBQ40857335-B8A3D4E7-3BF2-49A5-A6EF-BC3425BE18E4Q41673040-EDD88E13-3461-4EDF-872C-256143FAED2CQ41919609-97A202A0-20F7-448D-BCD9-D64D43A1DAD4Q47149904-FF23CC4D-DD6D-4382-A346-D89A1A1A5C46Q47402298-E802EE7A-9305-4B4C-86EC-F8201D88521CQ47547227-5921C74E-87F8-42F0-99B7-536271EC293EQ47569554-6BC01536-506D-4E8A-A394-27778421399AQ47593872-A0A5407F-AE23-4063-ABC6-CDF8C3B3E6CAQ47606236-5B418E16-D79F-46E0-ACBA-C583D52F9398Q49997050-B720C86B-F387-4AEC-9598-7F423AFF0719
P2860
Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immunological aspects of antiv ...... hepatitis C virus infections.
@ast
Immunological aspects of antiv ...... hepatitis C virus infections.
@en
type
label
Immunological aspects of antiv ...... hepatitis C virus infections.
@ast
Immunological aspects of antiv ...... hepatitis C virus infections.
@en
prefLabel
Immunological aspects of antiv ...... hepatitis C virus infections.
@ast
Immunological aspects of antiv ...... hepatitis C virus infections.
@en
P2860
P356
P1433
P1476
Immunological aspects of antiv ...... hepatitis C virus infections.
@en
P2093
Barbara Rehermann
P2860
P304
P356
10.1002/HEP.27323
P407
P5008
P577
2015-02-01T00:00:00Z